First human test of BIIB144 begins: safety first
NCT ID NCT07662148
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This study is the first time the experimental drug BIIB144 is given to humans. Researchers want to see if a single dose is safe and how the body handles it. About 48 healthy adults will receive either BIIB144 or a placebo by IV. The results will help decide if and how to test the drug in people with certain diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BIIB144
- What this could lead to
- If safe, this could pave the way for future studies of BIIB144 in people with specific diseases.
- What could go wrong
- This is a very early, first-in-human trial with only 48 healthy volunteers. The drug may cause side effects or not work as hoped in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Las Vegas Clinical Research Unit, PPD Development, LP
RECRUITINGLas Vegas, Nevada, 89113, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?